Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03412812 · ClinicalTrials.gov registry record · NA
A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT03412812: Completed NA study, sponsored by University of Alabama at Birmingham.
NCT03412812 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03412812, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.
Primary Outcome
To determine the maximum tolerated dose of five fraction stereotactic radiotherapy for patients with either tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter
Interventions
- RADIATION 6 Gy
- RADIATION 7 Gy
- RADIATION 8 Gy
- RADIATION 9 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2025-10-01 |
| Phase | NA |
What the finished NCT03412812 record still lists
NCT03412812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which 6 Gy is the first listed.
NCT03412812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03412812 about?
NCT03412812 is a clinical study titled "A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases". This study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.
What is the current status of trial NCT03412812?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2018-07-30. Estimated completion is 2025-10-01.
What interventions are being tested in trial NCT03412812?
The interventions under investigation include: 6 Gy (RADIATION), 7 Gy (RADIATION), 8 Gy (RADIATION), 9 Gy (RADIATION).
Who is sponsoring clinical trial NCT03412812?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03412812's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI